Literature DB >> 12464651

In vivo antitumor activity of Sindbis viral vectors.

Jen-Chieh Tseng1, Brandi Levin, Tadamichi Hirano, Herman Yee, Christine Pampeno, Daniel Meruelo.   

Abstract

BACKGROUND: Sindbis virus, a blood-borne virus transmitted by mosquitoes, has been used as a vector to efficiently express exogenous genes in vitro and in vivo and to induce apoptosis. Because Sindbis virus infects mammalian cells by interacting with the high-affinity laminin receptors, which are expressed at higher levels in several human cancers than in normal cells, we determined whether a Sindbis viral vector could be used to target cancers in vivo.
METHODS: C.B-17-SCID mice with established xenografts were given daily intraperitoneal injections of the Sindbis viral vector SinRep/LacZ containing the bacterial beta-galactosidase gene. Control mice were untreated or received injections with phosphate-buffered saline. Tumor size was measured daily. Expression of beta-galactosidase and Factor VIII (a marker for endothelial cells) was determined by immunohistochemical staining of tumor sections. Apoptosis was analyzed by TUNEL (terminal deoxynucleotidyl transferase [TdT]-mediated dUTP nick end labeling) staining. C.B-17-SCID beige mice, which lack natural killer (NK) cells, were used to assess the importance of NK cells in antitumor efficacy of Sindbis viral vectors.
RESULTS: Tumors from mice treated with SinRep/LacZ were statistically significantly smaller than tumors from control mice. This effect was observed for tumor xenografts derived from BHK (kidney, hamster), LS174T (colon, human), HT29 (colon, human), and CFPAC (pancreas, human) cells. Expression of beta-galactosidase co-localized with that of Factor VIII in tumor sections. Tumors from SinRep/LacZ-treated mice contained more apoptotic cells than tumors from control mice. Complete tumor regression was observed in three of five C.B-17-SCID mice but in none of five C.B-17-SCID beige mice treated with SinRep/LacZ.
CONCLUSION: Sindbis viral vectors efficiently targeted tumors in vivo, were apparently delivered through the circulation, and were more effective in the presence of NK cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12464651     DOI: 10.1093/jnci/94.23.1790

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  18 in total

1.  Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.

Authors:  Tomer Granot; Yoshihide Yamanashi; Daniel Meruelo
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

2.  Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.

Authors:  Pong-Yu Huang; Jih-Huong Guo; Lih-Hwa Hwang
Journal:  Mol Ther       Date:  2011-11-08       Impact factor: 11.454

3.  Oncolytic virotherapy for ovarian cancer.

Authors:  Shoudong Li; Jessica Tong; Masmudur M Rahman; Trevor G Shepherd; Grant McFadden
Journal:  Oncolytic Virother       Date:  2012-08

4.  ATM kinase is activated by sindbis viral vector infection.

Authors:  Christine Pampeno; Alicia Hurtado; Daniel Meruelo
Journal:  Virus Res       Date:  2012-03-29       Impact factor: 3.303

5.  Semliki forest virus-induced endoplasmic reticulum stress accelerates apoptotic death of mammalian cells.

Authors:  Gerald Barry; Rennos Fragkoudis; Mhairi C Ferguson; Aleksei Lulla; Andres Merits; Alain Kohl; John K Fazakerley
Journal:  J Virol       Date:  2010-04-28       Impact factor: 5.103

6.  Sindbis viral vector induced apoptosis requires translational inhibition and signaling through Mcl-1 and Bak.

Authors:  Lisa Venticinque; Daniel Meruelo
Journal:  Mol Cancer       Date:  2010-02-12       Impact factor: 27.401

7.  Activation of cytotoxic and regulatory functions of NK cells by Sindbis viral vectors.

Authors:  Tomer Granot; Lisa Venticinque; Jen-Chieh Tseng; Daniel Meruelo
Journal:  PLoS One       Date:  2011-06-02       Impact factor: 3.240

8.  Oncolytic activity of Sindbis virus in human oral squamous carcinoma cells.

Authors:  K Saito; K Uzawa; A Kasamatsu; K Shinozuka; K Sakuma; M Yamatoji; M Shiiba; Y Shino; H Shirasawa; H Tanzawa
Journal:  Br J Cancer       Date:  2009-07-28       Impact factor: 7.640

9.  Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor.

Authors:  J-C Tseng; T Granot; V DiGiacomo; B Levin; D Meruelo
Journal:  Cancer Gene Ther       Date:  2009-10-02       Impact factor: 5.987

Review 10.  Viral Proteins as Emerging Cancer Therapeutics.

Authors:  Ekta Manocha; Arnaldo Caruso; Francesca Caccuri
Journal:  Cancers (Basel)       Date:  2021-05-03       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.